Orion and Menarini collaborate on budesonide-formoterol Easyhaler for asthma and COPD

Finnish drugmaker Orion Corp (Nasdaq OMX: ORNAV) has entered into a collaboration agreement with Italy’s largest drugmaker Menarini, for the co-marketing of budesonide-formoterol Easyhaler combination product in Germany, Italy, Spain, and Portugal.

In addition, the parties have agreed on an exclusive license and distribution arrangement in France and Turkey. Both companies will market budesonide-formoterol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) under their own brands accompanied by the Easyhaler umbrella brand, as applicable.

Respiratory is one of the key strategic areas for family-owned Menarini. The collaboration with Menarini reinforces Orion's presence throughout Europe and is in line with Orion's strategy to strengthen its marketing position in Europe and the sales coverage through partnerships. The co-marketing area - in which both companies present their own product brands under the Easyhaler umbrella brand - covers Germany, Italy, Spain, and Portugal. Orion will retain exclusive marketing rights for the Nordic countries, UK and Eastern Europe where the company is currently promoting Easyhaler products. Orion will manufacture the budesonide-formoterol Easyhaler product covered by the agreement.